Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disorder characterized by intense pruritus and eczematous lesions, significantly impacting patients’ quality of life. Current treatment options include topical therapies (e.g., corticosteroids, calcineurin inhibitors, and topical Janus kinase JAK inhibitors), phototherapy, and systemic agents such as oral corticosteroids and JAK inhibitors. Advances in the understanding of AD immunopathogenesis have facilitated the development of targeted biologic therapies. Lebrikizumab, a humanized monoclonal antibody that selectively inhibits interleukin‐13 (IL‐13) signaling, has emerged as a potential therapeutic option for moderate‐to‐severe disease. This narrative review summarizes the evolving landscape of AD management, focusing on the mechanism of action, clinical efficacy, and safety profile of lebrikizumab, with evidence derived from Phase II and III clinical trials. It has been associated with improvements in skin clearance, reduction in pruritus, and enhanced quality of life. Its safety profile appears generally acceptable, with most reported adverse events being mild to moderate. Overall, it may serve as a valuable addition to current therapeutic options for atopic dermatitis, although further long‐term and comparative studies are needed to better establish its role in clinical practice.
Mushtaq et al. (Thu,) studied this question.